Laura Xanders
Family · Washington, DCNPI 1346581246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,476 of the $108,709 with a category attached, or 69.4%. AbbVie accounts for 60.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $39,045, 2.4 times the $16,309 reported in 2021. Among family clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $324.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Pfizer$23K
- Lundbeck LLC$13K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Amgen$1K
- Teva Pharmaceuticals USA, Inc.$324
- plus $303 from 6 others
Across 2 payments — averaging $555.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1K
What the payments were for
- Consulting fees$20,79019%
- Speaking & faculty fees$75,47669%
- Travel & lodging$5,5885%
- Food & beverage$6,5246%
- Education$3310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 209 | $65,273 |
| Pfizer | 56 | $23,178 |
| Lundbeck LLC | 41 | $12,657 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $5,724 |
| Amgen | 1 | $1,250 |
| Teva Pharmaceuticals USA, Inc. | 4 | $324 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 3 | $72 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Impel Pharmaceuticals Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,709 in reported general payments places this provider in the 95th percentile of 392 family providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 28 | $54,110 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $43,560 |
| QuliptaAtogepant | 25 | $30,345 |
| UbrelvyUbrogepant | 17 | $23,091 |
| Topiramate | 76 | $1,500 |
| Sumatriptan Succinate | 29 | $1,312 |
| Candesartan Cilexetil | 27 | $1,189 |
| Memantine Hcl | 54 | $501 |
| Amitriptyline Hcl | 25 | $361 |
| Nortriptyline Hcl | 12 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $23,178 | $54,11028 claims |
| AbbVieQulipta, Ubrelvy | $65,273 | $53,43642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 392 family providers in District of Columbia.
Other family in Washington
- Amy StewartWashington$489K
- Kara CouchWashington$144K
- Laura MackeWashington$39K
- Cassandra ThompsonWashington$11K
- Sharmin DiazWashington$9K
- Emily BertrandWashington$8K
- Ana Carrion-GelabertWashington$7K
- Chanda CopelandWashington$7K
- Suad NsouliWashington$6K
- Mitchell WhartonWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.